Actively Recruiting
'UROLIFE': a Patient-Directed Mobile Tool to Streamline the Quality of Life Assessment and Monitoring in Urothelial Carcinoma
Led by IRCCS San Raffaele · Updated on 2025-05-21
50
Participants Needed
1
Research Sites
4 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
This observational study focuses on patients diagnosed with urothelial carcinoma, aiming to develop a web app to help them better understand their condition and treatments. The study seeks to identify which contents and tools patients find most useful for supporting decision-making and improving education about urothelial carcinoma. It is sponsored by IRCCS San Raffaele and targets patients either about to start or already receiving systemic treatments. Participants will complete questionnaires designed by researchers to collect demographic and clinical information, including age, sex, education, treatment type, physical activity, caregiver status, and comfort using mobile devices. They will review paper questionnaires presenting potential app content such as quality of life assessments, symptom and side effect education, links to patient forums and support groups, and educational videos and podcasts. Patients can also suggest additional useful tools, and their feedback will be gathered through co-creation sessions using the Design Thinking method. During the study, participants will be asked to rate the proposed app contents, and researchers will measure the evaluation scores at three months. The study will also assess participants' eHealth literacy. The overall involvement includes answering questionnaires and participating in sessions to shape the future app. The findings aim to help design a patient-centered digital tool to support quality of life monitoring and education for urothelial carcinoma patients.
CONDITIONS
Brief Title
A Patient-Directed Mobile Tool to Streamline the QoL Assessment and Monitoring in Urothelial Carcinoma
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Histological diagnosis of urothelial carcinoma
- 18 years of age or older
- Candidate for systemic treatment with chemotherapy, immune-checkpoint inhibitors, antibody-drug conjugates, or targeted therapy, or already receiving such treatment
- Possession of a mobile device (e.g., smartphone or personal computer) with the physical and psychological ability to use it
- Understanding and speaking Italian
- Ability to sign informed consent
You will not qualify if you...
- No possession of a mobile device
- Unwillingness to give informed consent
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Your Study Journey
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
1 visit (in-person or remote)
Duration - 3 months
Participants complete questionnaires and engage in co-creation sessions to evaluate and provide feedback on the mobile tool contents related to quality of life, symptom management, and patient support.
Initial questionnaire and periodic assessments through the mobile tool
Trial Site Locations
Total: 1 location
1
IRCCS San Raffaele
Milan, Italy, Italy, 20132
Actively Recruiting
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
1
Similar Trials
Frequently Asked Questions
Have more questions? Get in touch with our team for quick support
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here